M
Milika Asanin
Researcher at University of Belgrade
Publications - 117
Citations - 1413
Milika Asanin is an academic researcher from University of Belgrade. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 18, co-authored 92 publications receiving 1030 citations. Previous affiliations of Milika Asanin include University of Bologna.
Papers
More filters
Journal ArticleDOI
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
Petar M. Seferovic,Petar M. Seferovic,Marija Polovina,Johann Bauersachs,Michael Arad,Tuvia Ben Gal,Lars Lund,Stephan B. Felix,Eloisa Arbustini,Alida L.P. Caforio,Dimitrios Farmakis,Gerasimos Filippatos,Elias Gialafos,Vladimir Kanjuh,Gordana Krljanac,Giuseppe Limongelli,Aleš Linhart,Alexander R. Lyon,Ružica Maksimović,Davor Milicic,Ivan Milinković,Michel Noutsias,Ali Oto,Öztekin Oto,Sinisa U. Pavlovic,Massimo F Piepoli,Arsen D. Ristić,Giuseppe M.C. Rosano,Hubert Seggewiss,Milika Asanin,Jelena P. Seferovic,Jelena P. Seferovic,Frank Ruschitzka,Jelena Celutkiene,Tiny Jaarsma,Christian Mueller,Brenda Moura,Loreena Hill,Maurizio Volterrani,Yuri Lopatin,Marco Metra,Johannes Backs,Wilfried Mullens,Ovidiu Chioncel,Rudolf A. de Boer,Stefan D. Anker,Claudio Rapezzi,Andrew J.S. Coats,Andrew J.S. Coats,Carsten Tschöpe +49 more
TL;DR: E epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies are focused on.
Journal ArticleDOI
Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study
Aleksandra Milosevic,Zorana Vasiljevic-Pokrajcic,Dejan Milasinovic,Jelena Marinkovic,Vladan Vukcevic,Branislav Stefanovic,Milika Asanin,Miodrag Dikic,Sanja Stankovic,Goran Stankovic +9 more
TL;DR: Immediate invasive strategy in NSTEMI patients is associated with lower rates of death or new MI compared with the delayed invasive strategy at early and midterm follow-up, mainly due to a decrease in the risk of new MI in the pre-catheterization period.
Journal ArticleDOI
Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction
Milika Asanin,Jovan Perunicic,Igor Mrdovic,Mihailo Matic,Bosiljka Vujisic-Tesic,Aleksandra Arandjelovic,Zorana Vasiljevic,Miodrag Ostojic +7 more
TL;DR: New‐onset atrial fibrillation (AF) after acute myocardial infarction (AMI) frequently occurs in association with postinfarction complications, particularly with heart failure (HF).
Journal ArticleDOI
Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry
Mitja Lainscak,Ivan Milinković,Marija Polovina,Marisa G. Crespo-Leiro,Lars Lund,Stefan D. Anker,Cécile Laroche,Roberto Ferrari,Andrew J.S. Coats,Theresa McDonagh,Gerasimos Filippatos,Gerasimos Filippatos,Aldo P. Maggioni,Massimo F Piepoli,Giuseppe M C Rosano,Frank Ruschitzka,Dragan Simic,Milika Asanin,Jean-Christophe Eicher,Mehmet Yilmaz,Petar M. Seferovic +20 more
TL;DR: This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality and hospitalization in chronic heart failure patients.
Journal ArticleDOI
Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial.
Marko Banovic,Bernard Iung,Jozef Bartunek,Milika Asanin,Branko Beleslin,Bojan Biocina,Filip Casselman,Mark Da Costa,Marek A. Deja,Hrvoje Gasparovic,Petr Kala,Lois Labrousse,Zlatibor Loncar,Jelena Marinkovic,Ivana Nedeljkovic,Milan Nedeljkovic,Peter Nemec,Serge D. Nikolic,Michael J. Pencina,Martin Penicka,Arsen D. Ristić,Faisal Sharif,Guy Van Camp,Marc Vanderheyden,Wojtek Wojakowski,Svetozar Putnik +25 more
TL;DR: The AVATAR trial will aim to assess outcomes among asymptomatic AS patients randomized to either elective early AVR or medical management with vigilant follow-up, and will be the first large prospective, randomized, controlled, multicenter clinical trial that will evaluate the safety and efficacy of elective AVR in this specific group of patients.